Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
HX531
Cat. No.:
OB0425LY-025
Appearance:
Solid
Purity:
99.87%
Identity:
Confirmed by NMR and LC-MS.
Size:
Add to basket
Product Overview
Description:
HX531 is a potent RXR antagonist having anti-apoptotic effect.
Synonyms:
HX 531; 188844-34-0; 4-(5,7,7,10,10-Pentamethyl-2-nitro-8,9-dihydronaphtho[2,3-b][1,5]benzodiazepin-12-yl)benzoic acid; 4-(7,8,9,10-Tetrahydro-5,7,7,10,10-pentamethyl-2-nitro-5H-benzo[b]naphtho[2,3-e][1,4]diazepin-12-yl)benzoic acid
CAS No.:
188844-34-0
Compound CID:
11755040
Formula:
C29H29N3O4
Formula Weight:
483.56
Specification
Target:
RAR/RXR; Apoptosis; MDM-2/p53
Pathway:
Metabolic enzyme/Protease; Vitamin D related/Nuclear receptor; Apoptosis
Solubility:
DMSO
Storage:
Storage at -20°C.
Applications:
HX531 can be used for diabetes and obesity research by leptin-dependent pathways and the p53-p21Cip1 pathway.
